Abcam, ab256950, Human IFNAR1 (Interferon alpha/beta receptor 1) knockout HeLa cell lysate

Size: 1Kit
IFNAR1 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon1 and Insertion of the selection cassette in exon1.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 7 bp deletion in exon1 and Insertion of the selection cassette in exon1.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-IFNAR1, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Interferon alpha/beta receptor 1 also known as IFNAR1 is an important component of the interferon receptor complex which includes the interferon beta receptor (IFNBR) and the broader class of interferon receptors. IFNAR1 is a transmembrane protein with a molecular mass of approximately 100 kDa. It shows expression in various tissues but predominantly in cells of the immune system. This expression pattern enables IFNAR1 to play a central role in mediating responses to interferon alpha and beta which are cytokines important in the immune response.
Biological function summary
IFNAR1 partners with interferon alpha receptor 2 (IFNAR2) to form a functional receptor complex. This complex binds interferons alpha and beta triggering signal transduction cascades vital for antiviral defense. Through this interaction IFNAR1 facilitates cellular immune responses including the activation of antiviral genes and modulation of cell proliferation. IFNAR1's role extends beyond immediate immune response influencing processes like cell differentiation and apoptosis.
Pathways
IFNAR1 is a participant in the JAK-STAT signaling pathway a significant pathway for transmitting cytokine signals. Upon interferon binding it activates the associated Janus kinases (JAKs) which in turn phosphorylate signal transducers and activators of transcription (STATs) specifically STAT1 and STAT2. This chain of events results in the transcription of interferon-stimulated genes that provide antiviral defenses and promote immune regulation. IFNAR1's engagement in these pathways makes it an integral part of immune system communication.
IFNAR1 associates strongly with autoimmune diseases and viral infections. In lupus an autoimmune disorder dysregulation in interferon signaling involving IFNAR1 contributes to disease progression. Moreover in viral infections like hepatitis C the response of IFNAR1 to interferon therapies can influence treatment outcomes. Understanding these connections facilitates therapeutic strategies that target interferon pathways for improved disease management.